All In Biotech

Drug Trial Radar · NCT02639130

GLP-1 Mediating DPP-4 Inhibition in Type 2 Diabetes

Quantification of the Contribution of GLP-1 to Mediating Insulinotropic Effects of DPP-4 Inhibition With Vildagliptin in Healthy Subjects and Type 2-diabetic Patients Using Exendin [9-39] as a GLP-1 Receptor Antagonist

Last checked: Nov 19, 2026Latest source record: Aug 16, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

67

Actual

Start

Feb 2008

Primary completion

Jan 2010

Study completion Jan 2010

Sponsor

Lead sponsor
Diabeteszentrum Bad Lauterberg im HarzAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 24, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Crossover
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 30 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To determine the extent to which the effects of treatment with LAF237 100 mg QD on glucagon secretion are mediated by Glucagon-like-peptide 1 (GLP-1) in type 2 diabetic patients and healthy subjects.

Conditions

  • Type 2 Diabetes

Interventions

  • Exendin [9-39]Drug

    Exendin \[9-39\] at 350 and 500 pmol/kg/min for infusion as challenge agent

  • PlaceboDrug

    Placebo infusion as challenge agent

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ratio of integrated insulin secretion rates (total AUC ISR) over 4 hour following the mealTime frame: 4 hour following the meal
  2. total AUC Glucose over 4 hour following the mealTime frame: 4 hour following the meal

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Diabeteszentrum Bad Lauterberg

    Bad Lauterberg im Harz, Lower Saxony, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.